But it also leaves you vulnerable to infections, impairs wound healing, and comes with side effects that sometimes rival the disease itself
Additional reductions are observed in inflammatory mediators including monocyte chemoattractant protein-1 (MCP-1), inducible nitric oxide (NO) synthase (iNOS), and NO production [66, 109, 110]
improved neurobehavioral outcomes
It is recognized for promoting angiogenesis (new blood vessel growth) and reducing inflammation, which aids tissue repair
Medically reviewed by Alan Lucks | MD , Alan Lucks MDPC Private Practice - New York on June 16th, 2025
Micro-dosing BPC-157 at 0.1 to 0.25 mg daily shows promising results for managing chronic inflammatory conditions with potentially fewer side effects than standard protocols